Goldman Sachs Cuts IONIS Price Target to $56

Goldman Sachs has reduced its price target for Ionis Pharmaceuticals (IONS) to $56.00, down from $69.00, indicating a cautious outlook on the company's near-term performance.

The Neutral rating maintains by Goldman Sachs reflects concerns about IONS' growth prospects and market conditions, which investors should consider when evaluating their positions.

IONIS has a broad pipeline of nearly 32 drugs targeting various diseases, including cardiovascular, metabolic, neurological, and rare diseases. The company operates within the healthcare sector, specifically in the biotechnology industry.

The GF Value™ for IONS is currently set at $48.19, while the stock is trading at $56.63, indicating that it is approximately 17.5% overvalued.